Ulf Mark Schneider
(born 1965) is the current CEO of Fresenius, a $26 billion global health care group.
Life and career
Schneider was born and raised in Germany and became a U.S. citizen in 2003. He holds a doctorate in economics from the University of St. Gallen, Switzerland, and an MBA from Harvard Business School. Schneider joined Fresenius in November 2001 and served as Chief Financial Officer of Fresenius Medical Care before assuming his current position in May, 2003. Previously, he was Group Finance Director for Gehe UK plc., a pharmaceutical wholesale and retail distributor, in Coventry, England. Schneider held several senior executive positions starting in 1989 with Gehe’s majority shareholder, Franz Haniel & Cie. GmbH, a diversified German industrial company. Under Schneider's leadership, Fresenius' revenue has almost tripled, the number of employees has more than tripled and net income has increased approximately eightfold. Since Schneider became CEO, Fresenius has also carried out a number of major strategic acquisitions: the private hospital chain HELIOS Kliniken in 2005; U.S. dialysis provider Renal Care Group, in 2006; U.S. pharmaceutical company APP Pharmaceuticals, in 2008; Liberty Dialysis, another major dialysis provider in the United States, in 2011; and, in 2014, the purchase of 41 hospitals from Rhön-Klinikum, through which HELIOS became the largest private hospital operator in Germany.
The management challenges of global growth and future strategies in the health care and pharmaceutical industries are of particular interest to Schneider.
Schneider chairs the European Advisory Board of Harvard Business School, and serves on the Board of Directors of the American chemical company DuPont.
Source @ Wikipedia